Young researchers receive boost to develop innovative treatment for melanoma

Young researchers receive boost to develop innovative treatment for melanoma

4 March 2021

Melanoma research has received a boost with two researchers from Melanoma Institute Australia (MIA) and The University of Sydney awarded highly competitive fellowships from Cancer Institute NSW.

Dr Tuba Nur Gide and Dr Camelia Quek were each awarded an Early Career Fellowship to support their innovative research into melanoma treatment. The Fellowships are designed to encourage promising early career researchers who recently completed their PhD to choose cancer as their selected field of research endeavor.

“It is deeply rewarding to see these two talented young researchers receive these prestigious Fellowships,” said Prof Richard Scolyer, Co-Medical Director of MIA. “Their dedication and passion for developing more effective treatments for patients is inspiring and we are proud to have them as part of our team.”

While immunotherapy is proving effective in treating many advanced melanoma patients, others either don’t respond or develop resistance. These treatments can also cause significant, life-altering side-effects. Dr Nur Guide and Dr Quek are trying to identify which patients will respond to treatment and why, as this is essential to improving survival and quality of life for advanced melanoma patients around the world.

Prof Georgina Long AO, Co-Medical Director of MIA, is delighted that Dr Nur Guide and Dr Quek have received funding to pursue their research endeavors.

“Supporting medical research into Australia’s national cancer is vital to improving care for melanoma patients,” commented Prof Long. “With Australia at the forefront of global melanoma research efforts, it is exciting that our early career researchers will have the support they need to pioneer new treatments to improve the lives of melanoma patients.”

Personalised immunotherapy

There are currently no effective tests to determine which patients will respond to immunotherapy and which will need another treatment to stop their melanoma progressing. Dr Nur Gide’s research project is investigating this by assessing the accuracy of a panel of predictive tests with the aim of taking this out of the lab and into the everyday clinic setting.

“Once a patient enters a clinic, in real time we will be able to determine if they are likely to respond to treatment,” said Dr Nur Gide. “This will allow patients to avoid unnecessary toxicities and limit costs to patients and the healthcare system, as well as ultimately improving survival outcomes.”

The research project will help change the way cancer patients are treated and selected for clinical trials, by moving away from the one-size-fits-all approach and towards a precision approach to delivering effective immunotherapies on a personal basis.

“It is a great honour to have been awarded the CINSW Early Career Fellowship,” said Dr Nur Gide. “It will allow me to continue conducting research that will positively impact the lives of patients with advanced cancer and contribute to achieving our goal of zero deaths from melanoma.”

Understanding resistance to immunotherapy

Dr Camelia Quek’s research is trying to understand why some people with advanced melanoma become resistant to immunotherapy after they receive treatment. She is investigating the relatively new concept that a tumour and the microenvironment around it can evolve, causing resistance to immunotherapy. She will be using innovative computational biology methods to identify which genes and proteins involved in immune control are altered.

“Ultimately my research will provide significant benefits in developing innovative drug combination strategies and novel therapeutic targets to improve treatment for melanoma patients,” commented Dr Quek. “This will improve survival for patients, as well as improve their quality of life.”

“This fellowship will provide a fantastic opportunity for me to continue making discoveries that enable the development of innovative treatment strategies and biomarkers, ensuring the prolonged survival of Australians with cancer,” she said.

 

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
02 Dec 2020

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.

A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

Tags: melanoma
It's 'Game On Mole' this summer!
01 Dec 2020

It's 'Game On Mole' this summer!

All Australians are urged to join the fight against melanoma this summer. 

Tags: melanoma
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  
27 Nov 2020

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  

The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research. 

Tags: melanoma
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
24 Nov 2020

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award

A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 Nov 2020

MIA researchers feature on prestigious Highly Cited Researchers 2020 List

The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Tags: melanoma
Game On Mole is back this summer!
13 Nov 2020

Game On Mole is back this summer!

The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

Tags: melanoma
RCPA recognition for Professor Richard Scolyer.
12 Nov 2020

RCPA recognition for Professor Richard Scolyer.

Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Tags: melanoma
Professor Georgina Long hands on baton of SMR Presidency
31 Oct 2020

Professor Georgina Long hands on baton of SMR Presidency

Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.

Tags: melanoma
City2Surf 2020
11 Sep 2020

City2Surf 2020

Join in the fun of the virtual event, and together we can run over melanoma!

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts at MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts from MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Melanoma Supportive Care Needs research study. 
03 Sep 2020

Melanoma Supportive Care Needs research study. 

Participate in our online survey and help us understand the support needs of melanoma patients and carers.

Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

Research reveals long-term benefit of adjuvant therapy for Stage III melanoma

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New online melanoma risk calculators critical to saving lives
28 Aug 2020

New online melanoma risk calculators critical to saving lives

Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.

Tags: melanoma
Professor Richard Scolyer receives University of Sydney Alumni Award.
24 Aug 2020

Professor Richard Scolyer receives University of Sydney Alumni Award.

MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.

Tags: melanoma
Uniting together despite the distance
21 Aug 2020

Uniting together despite the distance

More than 120 MIA clinicians, researchers and staff came together online to share research highlights.

Tags: melanoma
Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
03 Aug 2020

Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.

For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.

Tags: melanoma
Important Update: Masks required at Poche Centre
24 Jul 2020

Important Update: Masks required at Poche Centre

As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask. 

Tags: melanoma
A Critical Nexus:The Clinician and the Researcher.
14 Jul 2020

A Critical Nexus:The Clinician and the Researcher.

In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.    

Tags: melanoma